| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $75M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Over the last 12 months, insiders at CNS Pharmaceuticals, Inc. have bought $0 and sold $0 worth of CNS Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at CNS Pharmaceuticals, Inc. have bought $56,300 and sold $133,114 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 166,666 shares for transaction amount of $50,000 was made by Climaco John M (Chief Executive Officer) on 2024‑02‑01.
| Increased Positions | 5 | +50% | 109,576 | +445.14% |
| Decreased Positions | 3 | -30% | 9,939 | -40.38% |
| New Positions | 4 | New | 108,197 | New |
| Sold Out Positions | 2 | Sold Out | 30 | Sold Out |
| Total Postitions | 12 | +20% | 124,253 | +404.77% |